Gyre Therapeutics (NASDAQ:GYRE) Stock Price Down 4.7% – Time to Sell?

Gyre Therapeutics, Inc. (NASDAQ:GYRE)’s share price dropped 4.7% during mid-day trading on Friday . The stock traded as low as $9.63 and last traded at $9.74. Approximately 48,133 shares were traded during trading, a decline of 40% from the average daily volume of 80,171 shares. The stock had previously closed at $10.22.

Analyst Upgrades and Downgrades

Separately, Noble Financial initiated coverage on shares of Gyre Therapeutics in a research note on Tuesday, March 11th. They issued an “outperform” rating for the company.

Gyre Therapeutics Price Performance

The firm’s 50 day moving average price is $11.31 and its two-hundred day moving average price is $12.23.

Gyre Therapeutics (NASDAQ:GYRE) last released its quarterly earnings data on Monday, March 17th. The company reported $0.01 earnings per share for the quarter, missing the consensus estimate of $0.04 by ($0.03). The company had revenue of $27.87 million during the quarter, compared to the consensus estimate of $23.50 million. Gyre Therapeutics had a negative net margin of 84.57% and a negative return on equity of 118.43%.

Insider Activity at Gyre Therapeutics

In related news, President Songjiang Ma sold 2,000 shares of Gyre Therapeutics stock in a transaction on Thursday, December 26th. The shares were sold at an average price of $12.70, for a total value of $25,400.00. Following the completion of the sale, the president now owns 2,928,467 shares of the company’s stock, valued at approximately $37,191,530.90. This trade represents a 0.07 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. In the last 90 days, insiders sold 36,054 shares of company stock valued at $411,597. 19.52% of the stock is owned by company insiders.

Institutional Trading of Gyre Therapeutics

Several hedge funds have recently bought and sold shares of the business. Bank of America Corp DE grew its position in Gyre Therapeutics by 40.4% in the 4th quarter. Bank of America Corp DE now owns 6,937 shares of the company’s stock valued at $84,000 after purchasing an additional 1,996 shares during the period. Northern Trust Corp grew its position in Gyre Therapeutics by 9.1% in the 4th quarter. Northern Trust Corp now owns 103,382 shares of the company’s stock valued at $1,251,000 after purchasing an additional 8,624 shares during the period. Barclays PLC grew its position in Gyre Therapeutics by 13.5% in the 4th quarter. Barclays PLC now owns 10,543 shares of the company’s stock valued at $128,000 after purchasing an additional 1,255 shares during the period. Wells Fargo & Company MN grew its position in Gyre Therapeutics by 29.4% in the 4th quarter. Wells Fargo & Company MN now owns 4,016 shares of the company’s stock valued at $49,000 after purchasing an additional 913 shares during the period. Finally, Charles Schwab Investment Management Inc. boosted its holdings in Gyre Therapeutics by 0.8% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 114,566 shares of the company’s stock worth $1,386,000 after acquiring an additional 918 shares during the last quarter. Institutional investors and hedge funds own 23.99% of the company’s stock.

Gyre Therapeutics Company Profile

Gyre Therapeutics, Inc, a biopharmaceutical company, primarily focuses on the development and commercialization of Hydronidone for the treatment of Metabolic Dysfunction Associated Steatohepatitis in the United States. Its Hydronidone is also being evaluated for the treatment of liver fibrosis across a spectrum of chronic liver diseases.